Ticker
AFMD

Price
0.60
Stock movement up
+0.02 (3.99%)
Company name
Affimed NV
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
90.01M
Ent value
-77.59M
Price/Sales
2.22
Price/Book
0.50
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-43.14%
3 year return
-53.97%
5 year return
-29.58%
10 year return
-
Last updated: 2024-02-19

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

AFMD does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.22
Price to Book0.50
EV to Sales-1.91

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count149.34M
EPS (TTM)-0.51
FCF per share (TTM)-0.70

Income statement

Loading...
Income statement data
Revenue (TTM)40.53M
Gross profit (TTM)0.00
Operating income (TTM)-82.18M
Net income (TTM)-75.65M
EPS (TTM)-0.51
EPS (1y forward)-0.80

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-202.75%
Profit margin (TTM)-186.64%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash222.90M
Net receivables1.69M
Total current assets230.55M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets236.40M
Accounts payable15.08M
Short/Current long term debt18.73M
Total current liabilities40.83M
Total liabilities55.30M
Shareholder's equity181.10M
Net tangible assets179.55M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-101.57M
Capital expenditures (TTM)2.61M
Free cash flow (TTM)-104.18M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-41.77%
Return on Assets-32.00%
Return on Invested Capital-37.90%
Cash Return on Invested Capital-52.19%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.58
Daily high0.60
Daily low0.57
Daily Volume474K
All-time high21.93
1y analyst estimate7.77
Beta2.57
EPS (TTM)-0.51
Dividend per share-
Ex-div date-
Next earnings date21 Mar 2024

Downside potential

Loading...
Downside potential data
AFMDS&P500
Current price drop from All-time high-97.25%-0.50%
Highest price drop-98.55%-56.47%
Date of highest drop27 Oct 20239 Mar 2009
Avg drop from high-78.27%-11.40%
Avg time to new high95 days13 days
Max time to new high2162 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
AFMD (Affimed NV) company logo
Marketcap
90.01M
Marketcap category
Small-cap
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that is in Phase IIa clinical trial for CD30-positive lymphoma, Phase I clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Employees
0
Investor relations
-
SEC filings
CEO
Adolf Hoess
Country
USA
City
Heidelberg
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...